Topic: depression

Sage Therapeutics Zulresso product image

4. Zulresso

Two weeks after an FDA panel recommended Zulresso for approval in a near-unanimous vote, the agency put off its decision on the drug so it could work on a risk evaluation and mitigation strategy.
allergan irvine

9. Rapastinel

Rapastinel, a depression drug that Allergan picked up via its $560 million acquisition of Naurex in 2015, hit the buffers after missing its objectives in no fewer than four pivotal trials this year and has now been abandoned.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.